Please assess the completion status of the following clinical trial:

Trial Title: Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria :~* Healthy male /or female subjects,~* aged 18 to 65 years old,~* with LDL-C \> 130 mg/dL~* not receiving lipid lowering therapy.~Exclusion criteria:~* Healthy subjects with history or presence of clinically relevant illness.~* Subjects currently taking statins, ezetimibe or fenofibrate.~* The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Alirocumab + Ezetimibe Placebo (Type: EXPERIMENTAL): Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe placebo
- Alirocumab + Ezetimibe (Type: EXPERIMENTAL): Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe
- Alirocumab + Fenofibrate (Type: EXPERIMENTAL): Subcutaneous (SC) injections of alirocumab added to oral administration of fenofibrate

Based on this trial design, predict the completion outcome and termination type (if applicable).